Table 3.
Association between CYP3A4*22 and neurotoxicitya
| No. of patients | Neurotoxicity CTCAE grade 0 | Neurotoxicity CTCAE grade 1 | Neurotoxicity CTCAE grade 2 | Neurotoxicity CTCAE grade 3 | P-valueb | |
|---|---|---|---|---|---|---|
| Exploratory Cohort | 254 | |||||
| Female | 122 | |||||
| C/C | 105 | 50 (48) | 46 (44) | 8(8) | 1(1) | |
| C/T+T/T | 17 | 4(24) | 8 (47) | 4(24) | 1(6) | 0.043 |
| Male | ||||||
| C/C | 114 | 85 (75) | 24(21) | 5(4) | - | |
| C/T + T/T | 18 | 13 (72) | 4(22) | 1(6) | - | 0.90 |
| Validation Cohort | 237 | |||||
| Female | 110 | |||||
| C/C | 98 | 30(31) | 53 (54) | 13(13) | 2(2) | |
| C/T+T/T | 12 | 6 (50) | 4(33) | - | 2(17) | 0.036 |
| Male | 127 | |||||
| C/C | 113 | 80 (71) | 28(25) | 5(4) | - | |
| C/T + T/T | 14 | 8 (57) | 4(29) | - | 2(14) | 0.025 |
P-values are calculated with the chi-square test
a
All data are represented as absolute number with percentage in parentheses, unless stated otherwise
b
P-values < 0.05 represents differentially distributed neurotoxicity scores between non-carriers and carriers of the variant allele and are calculated with the Fisher exact test.
Abbreviations: CTCAE, National Cancer Institute’s Common Terminology Criteria for Adverse Events version 2–4